PHILADELPHIA — Risankizumab outperformed placebo in endoscopic improvement and remission through 52 weeks of maintenance therapy in moderately to severely active ulcerative colitis, regardless of induction outcomes, according to data. In a post-hoc analysis of the phase 3 COMMAND study, Remo Panaccione, MD, FRCPC, professor of medicine and director of the Inflammatory Bowel Disease Unit at
The 2024 GOLD International COPD Conference will be held Nov. 11 and 12 in Philadelphia and online, featuring presentations from various speakers on important topics…
We read with interest the letter from Han et al about our study1 and we thank those authors for underlining points to be discussed about…
BOSTON — A multimodal fusion model outperformed transthoracic echocardiography in identifying pulmonary hypertension, according to a study presented at the CHEST Annual Meeting.This model could…
Ex-smokers with a light lifetime smoking burden had a CVD risk shortly after quitting similar to those who have never smoked, results from a cohort…
n this episode, Drs. Kevin El-Hayek and new co-host Dr. Jenny Shao talk to Past SAGES Presidents Drs. Hoarcio Asbun, Liane Feldman, John Mellinger, and…
Patients with systemic sclerosis demonstrate lower bone mineral density compared with the general population, with significant differences reported in women aged younger than 45 years,…
Less than 3% of patients tested for a bacterial STI in nearly a dozen EDs were also tested for HIV, demonstrating widespread nonadherence to a…
Respiratory syncytial virus vaccines proved highly effective at preventing hospitalization and ED visits in older adults, even in those with immunocompromising conditions, results from an…
People who are not married may be over 80% more likely to have depressive symptoms compared with their married peers, according to a multinational analysis…
Ex-smokers with a light lifetime smoking burden had a CVD risk shortly after quitting similar to those who have never smoked, results from a cohort…
